Literature DB >> 9776302

Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease.

K S McNaught1, P A Carrupt, C Altomare, S Cellamare, A Carotti, B Testa, P Jenner, C D Marsden.   

Abstract

The cause of neurodegeneration in Parkinson's disease (PD) remains unknown. However, isoquinoline derivatives structurally related to the selective dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its active metabolite, 1-methyl-4-phenylpyridinim (MPP+), have emerged as candidate endogenous neurotoxins causing nigral cell death in Parkinson's disease. Isoquinoline derivatives are widely distributed in the environment, being present in many plants and foodstuffs, and readily cross the blood-brain barrier. These compounds occur naturally in human brain where they are synthesized by non-enzymatic condensation of biogenic amines (e.g. catecholamines and phenylethylamine) with aldehydes, and are metabolized by cytochrome P450s and N-methyltransferases. In addition, isoquinoline derivatives are oxidized by monoamine oxidases to produce isoquinolinium cations with the concomitant generation of reactive oxygen species. Neutral and quaternary isoquinoline derivatives accumulate in dopaminergic nerve terminals via the dopamine re-uptake system, for which they have moderate to poor affinity as substrates. Several isoquinoline derivatives are selective and more potent inhibitors of NADH ubiquinone reductase (complex I) and alpha-ketoglutarate dehydrogenase activity in mitochondrial fragments than MPP+, and lipophilicity appears to be important for complex I inhibition by isoquinoline derivatives. However, compared with MPP+, isoquinoline derivatives are selective but less potent inhibitors of NADH-linked respiration in intact mitochondria, and this appears to be a consequence of their rate-limiting ability to cross mitochondrial membranes. Although both active and passive processes are involved in the accumulation of isoquinoline derivatives in mitochondria, inhibition of respiration is determined by steric rather than electrostatic properties. Compared with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or MPP+, isoquinoline derivatives show selective but relatively weak toxicity to dopamine-containing cells in culture and following systemic or intracerebral administration to experimental animals, which appears to be a consequence of poor sequestration of isoquinoline derivatives by mitochondria and by dopamine-containing neurones. In conclusion, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-like cytotoxic characteristics of isoquinoline derivatives and the endogenous/environmental presence of these compounds make it conceivable that high concentrations of and/or prolonged exposure to isoquinoline derivatives might cause neurodegeneration and Parkinson's disease in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9776302     DOI: 10.1016/s0006-2952(98)00142-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  4-Organoseleno-Isoquinolines Selectively and Reversibly Inhibit the Cerebral Monoamine Oxidase B Activity.

Authors:  Tuane Bazanella Sampaio; Juliana Trevisan Da Rocha; Marina Prigol; Rogério Aquino Saraiva; Pablo Froner Nogara; André Luiz Agnes Stein; João Batista Teixeira da Rocha; Gilson Zeni; Cristina Wayne Nogueira
Journal:  J Mol Neurosci       Date:  2016-04-06       Impact factor: 3.444

Review 2.  The alpha-ketoglutarate-dehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration.

Authors:  Gary E Gibson; John P Blass; M Flint Beal; Victoria Bunik
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 3.  Not Just from Ethanol. Tetrahydroisoquinolinic (TIQ) Derivatives: from Neurotoxicity to Neuroprotection.

Authors:  Alessandra T Peana; Valentina Bassareo; Elio Acquas
Journal:  Neurotox Res       Date:  2019-05-02       Impact factor: 3.911

Review 4.  Astrocytes and therapeutics for Parkinson's disease.

Authors:  Phillip M Rappold; Kim Tieu
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

5.  Chromosomal loci influencing the susceptibility to the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  Marco Sedelis; Katja Hofele; Rainer K W Schwarting; Joseph P Huston; John K Belknap
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

6.  The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway.

Authors:  Mei Cui; Radha Aras; Whitney V Christian; Phillip M Rappold; Mamata Hatwar; Joseph Panza; Vernice Jackson-Lewis; Jonathan A Javitch; Nazzareno Ballatori; Serge Przedborski; Kim Tieu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-29       Impact factor: 11.205

7.  Neurotoxic effects of tetrahydroisoquinolines and underlying mechanisms.

Authors:  Young-Joon Surh; Hyun-Jung Kim
Journal:  Exp Neurobiol       Date:  2010-09-30       Impact factor: 3.261

8.  Antidepressant-like effect of tetrahydroisoquinoline amines in the animal model of depressive disorder induced by repeated administration of a low dose of reserpine: behavioral and neurochemical studies in the rat.

Authors:  Lucyna Antkiewicz-Michaluk; Agnieszka Wąsik; Edyta Możdżeń; Irena Romańska; Jerzy Michaluk
Journal:  Neurotox Res       Date:  2014-01-10       Impact factor: 3.911

Review 9.  Brain sites of movement disorder: genetic and environmental agents in neurodevelopmental perturbations.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

Review 10.  1-Methyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine with unexpected mechanism of action: new vistas of therapeutic application.

Authors:  Lucyna Antkiewicz-Michaluk; Agnieszka Wąsik; Jerzy Michaluk
Journal:  Neurotox Res       Date:  2013-05-30       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.